{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044224","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.886743+00:00","generated_at":"2026-05-30T03:07:07.308655+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anixa Biosciences presents updated positive Phase 1 data for breast cancer vaccine; Phase 2 planned for 2025","bullets":["Phase 1 trial of alpha-lactalbumin vaccine updated at SITC; data continue positive trend across 3 cohorts.","Vaccine safe and well tolerated; only notable side effect was injection-site irritation.","Over 70% of patients exhibited protocol-defined immune responses (interferon-gamma, interleukin-17).","Combination with Keytruda (Cohort 1c) showed no major adverse events; one Grade 3 injection-site reaction in a recently lactated patient.","Phase 2 neoadjuvant study with randomized control planned to commence in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044224","json":"https://secwatch.observer/filing/0001493152-24-044224.json","markdown":"https://secwatch.observer/filing/0001493152-24-044224.md","text":"https://secwatch.observer/filing/0001493152-24-044224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315224044224/0001493152-24-044224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315224044224/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:07:07.308655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}